Destroying Cancer at the Speed of Light®

Clinical Study Underway (63 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026

Stock Quote Today & Recent News Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.W | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

< Previous

Next >

By working with Health Canada and the FDA to approve the optimization of the clinical study design, analysis and reporting structure of Study II early in the process, Theralase® is able to much better align the clinical data collected in Study II with best practices and current expectations of the Canadian and US regulators; thereby, helping to avoid difficult to address questions at final review time

Roger DuMoulin-White, BSc, P.Eng, Pro.Dir, President and Chief Executive Officer

Current News (TSXV:TLT)

This company’s Photo Dynamic Therapy is transforming cancer treatment

Jocelyn Aspa 10 days ago

Theralase patents new cancer vaccine in Canada

Trevor Abes April 5, 2024

Theralase(R) Granted Canadian Cancer Vaccine Patent

Accesswire April 5, 2024

Theralase(R) Release's 4Q2023 Interim Financial Statements

Accesswire March 27, 2024

Theralase(R) to Host Advisory Board Meetings at Canadian Urological Association Bladder Cancer Forum and the American Urological Association

Accesswire March 26, 2024

Theralase donates laser therapy tech to help research Parkinson’s treatment

Jonathon Brown February 12, 2024

View More News ››

To date, the Theralase® Study II clinical data has demonstrated best-in-class performance for a single agent, providing high efficacy, durable response and a high safety profile, with no serious adverse events directly related to RuvidarTM or the TLC-3200 Medical Laser System

Roger DuMoulin-White, BSc, P.Eng, Pro.Dir, President and Chief Executive Officer

Opinion & Analysis (TSXV:TLT)

Pharmaceutical company treats bladder cancer with new tech

Ryan Dhillon January 8, 2024

Theralase is raising up to $5.3M to complete bladder cancer study

Coreena Robertson November 6, 2023

For Better or Worse? On the Verge of a New Era in Investing

Stockhouse Editorial April 1, 2021

Buzz on the Bullboards: A Big Picture Look at Small-Cap Opportunities

Stockhouse Editorial February 18, 2021

Buzz on the Bullboards: Tracking the Big Movers of 2020

Stockhouse Editorial December 17, 2020

Buzz on the Bullboards: T’is the Season for a Rebound?

Stockhouse Editorial December 3, 2020

View More Opinion ››

View more Bullboard ››

Connect with V.TLT

INVESTORS & MEDIA OVERVIEW FINANCIAL FILINGS PRESENTATIONS MEDIA FACT SHEETS MANAGEMENT

Investor Presentation

FACT SHEET

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

Clinical Study with 63 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
Best-in-class treatment for NMIBC (according to interim clinical data)
NMIBC (Non-Muscle-Invasive Bladder Cancer)

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250

Become a member today, It's free!